Trials / Sponsors / EyeBiotech Ltd.
EyeBiotech Ltd.
Industry · 7 registered clinical trials — 3 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Not Yet Recruiting | A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003) Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization | Phase 2 / Phase 3 | 2026-04-30 |
| Recruiting | A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002) Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization | Phase 2 / Phase 3 | 2026-03-27 |
| Recruiting | A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVO Neovascular Age-Related Macular Degeneration (NVAMD), Branch Retinal Vein Occlusion (BRVO) | Phase 2 | 2025-09-12 |
| Active Not Recruiting | A Study of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME Diabetic Macular Edema (DME) | Phase 2 / Phase 3 | 2025-04-16 |
| Active Not Recruiting | A 2-part Study Consisting of a Multiple Ascending Dose Safety Study in Participants With Macular Edema Followi Diabetic Macular Edema (DME), Neovascular Age-related Macular Degeneration (NVAMD), BRVO - Branch Retinal Vein Occlusion | Phase 1 / Phase 2 | 2024-11-12 |
| Active Not Recruiting | A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Partici Diabetic Macular Edema (DME) | Phase 2 / Phase 3 | 2024-08-07 |
| Completed | A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to As Neovascular Age-related Macular Degeneration (NVAMD), Diabetic Macular Edema (DME) | Phase 1 / Phase 2 | 2023-06-12 |